Forecasting the elimination of active trachoma: An empirical model

Background Great progress has been made toward the elimination of trachoma as a public-health problem. Mathematical and statistical models have been used to forecast when the program will attain the goal of the elimination of active trachoma, defined as prevalence of trachomatous inflammation-follic...

Full description

Saved in:
Bibliographic Details
Published inPLoS neglected tropical diseases Vol. 16; no. 7; p. e0010563
Main Authors Renneker, Kristen K, Emerson, Paul M, Hooper, P. J, Ngondi, Jeremiah M
Format Journal Article
LanguageEnglish
Published San Francisco Public Library of Science 11.07.2022
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background Great progress has been made toward the elimination of trachoma as a public-health problem. Mathematical and statistical models have been used to forecast when the program will attain the goal of the elimination of active trachoma, defined as prevalence of trachomatous inflammation-follicular in 1-9 year olds (TF.sub.1-9) <5%. Here we use program data to create an empirical model predicting the year of attaining global elimination of TF.sub.1-9. Methodology/Principal findings We calculated the mean number of years (95% CI) observed for an implementation unit (IU) to move from a baseline TF.sub.1-9 prevalence [greater than or equal to]5% to the elimination threshold, based on the region (Ethiopia vs. non-Ethiopia) and baseline prevalence category. Ethiopia IUs had significantly different rates of reaching the TF.sub.1-9 elimination threshold after a trachoma impact survey (TIS) compared to non-Ethiopia IUs across all baseline categories. We used those estimates to predict when remaining active trachoma-endemic IUs (TF.sub.1-9 [greater than or equal to]5%) would have their last round of mass drug administration (MDA) based on the mean number of years required and number of MDA rounds already completed. Our model predicts that elimination of TF.sub.1-9 will be achieved in 2028 in Ethiopia (95% CI: 2026-2033) and 2029 outside of Ethiopia (95% CI: 2023-2034), with some IUs in East Africa predicted to be the last requiring MDA globally. Conclusions/Significance Our empirical estimate is similar to those resulting from previous susceptible-infectious-susceptible (SIS) and mathematical models, suggesting that the forecast achievement of TF.sub.1-9 elimination is realistic with the caveat that although disease elimination progress can be predicted for most IUs, there is an important minority of IUs that is not declining or has not yet started trachoma elimination activities. These IUs represent an important barrier to the timely global elimination of active trachoma.
AbstractList Background Great progress has been made toward the elimination of trachoma as a public-health problem. Mathematical and statistical models have been used to forecast when the program will attain the goal of the elimination of active trachoma, defined as prevalence of trachomatous inflammation-follicular in 1-9 year olds (TF.sub.1-9) <5%. Here we use program data to create an empirical model predicting the year of attaining global elimination of TF.sub.1-9. Methodology/Principal findings We calculated the mean number of years (95% CI) observed for an implementation unit (IU) to move from a baseline TF.sub.1-9 prevalence [greater than or equal to]5% to the elimination threshold, based on the region (Ethiopia vs. non-Ethiopia) and baseline prevalence category. Ethiopia IUs had significantly different rates of reaching the TF.sub.1-9 elimination threshold after a trachoma impact survey (TIS) compared to non-Ethiopia IUs across all baseline categories. We used those estimates to predict when remaining active trachoma-endemic IUs (TF.sub.1-9 [greater than or equal to]5%) would have their last round of mass drug administration (MDA) based on the mean number of years required and number of MDA rounds already completed. Our model predicts that elimination of TF.sub.1-9 will be achieved in 2028 in Ethiopia (95% CI: 2026-2033) and 2029 outside of Ethiopia (95% CI: 2023-2034), with some IUs in East Africa predicted to be the last requiring MDA globally. Conclusions/Significance Our empirical estimate is similar to those resulting from previous susceptible-infectious-susceptible (SIS) and mathematical models, suggesting that the forecast achievement of TF.sub.1-9 elimination is realistic with the caveat that although disease elimination progress can be predicted for most IUs, there is an important minority of IUs that is not declining or has not yet started trachoma elimination activities. These IUs represent an important barrier to the timely global elimination of active trachoma.
Background Great progress has been made toward the elimination of trachoma as a public-health problem. Mathematical and statistical models have been used to forecast when the program will attain the goal of the elimination of active trachoma, defined as prevalence of trachomatous inflammation—follicular in 1–9 year olds (TF1–9) <5%. Here we use program data to create an empirical model predicting the year of attaining global elimination of TF1–9. Methodology/Principal findings We calculated the mean number of years (95% CI) observed for an implementation unit (IU) to move from a baseline TF1–9 prevalence ≥5% to the elimination threshold, based on the region (Ethiopia vs. non-Ethiopia) and baseline prevalence category. Ethiopia IUs had significantly different rates of reaching the TF1–9 elimination threshold after a trachoma impact survey (TIS) compared to non-Ethiopia IUs across all baseline categories. We used those estimates to predict when remaining active trachoma-endemic IUs (TF1–9 ≥5%) would have their last round of mass drug administration (MDA) based on the mean number of years required and number of MDA rounds already completed. Our model predicts that elimination of TF1–9 will be achieved in 2028 in Ethiopia (95% CI: 2026–2033) and 2029 outside of Ethiopia (95% CI: 2023–2034), with some IUs in East Africa predicted to be the last requiring MDA globally. Conclusions/Significance Our empirical estimate is similar to those resulting from previous susceptible-infectious-susceptible (SIS) and mathematical models, suggesting that the forecast achievement of TF1–9 elimination is realistic with the caveat that although disease elimination progress can be predicted for most IUs, there is an important minority of IUs that is not declining or has not yet started trachoma elimination activities. These IUs represent an important barrier to the timely global elimination of active trachoma.
Mathematical and statistical models have been used to forecast the global decline of active trachoma prevalence as a result of interventions against the disease. Here we used trachoma program data to create an empirical model predicting the year of attaining global elimination. We analyzed over 20 years of trachoma implementation and survey data to calculate the mean number of rounds of mass drug administration required for implementation units to fall below the elimination threshold for active trachoma. We then compared these means against the number of rounds of mass drug administration previously undertaken for all areas still above the elimination threshold to produce a forecast of the last year of antibiotic distribution for each implementation unit. Our model predicts that elimination will be achieved in 2028 in Ethiopia (95% CI: 2026–2033) and 2029 outside of Ethiopia (95% CI: 2023–2034), with areas in East Africa predicted to be the last requiring mass drug administration globally. However, although disease-elimination progress can be predicted for most implementation units, there is an important minority of implementation units that is not declining or has not yet begun implementation. These areas represent an important barrier to the timely global elimination of active trachoma.
Great progress has been made toward the elimination of trachoma as a public-health problem. Mathematical and statistical models have been used to forecast when the program will attain the goal of the elimination of active trachoma, defined as prevalence of trachomatous inflammation-follicular in 1-9 year olds (TF.sub.1-9) <5%. Here we use program data to create an empirical model predicting the year of attaining global elimination of TF.sub.1-9. We calculated the mean number of years (95% CI) observed for an implementation unit (IU) to move from a baseline TF.sub.1-9 prevalence [greater than or equal to]5% to the elimination threshold, based on the region (Ethiopia vs. non-Ethiopia) and baseline prevalence category. Ethiopia IUs had significantly different rates of reaching the TF.sub.1-9 elimination threshold after a trachoma impact survey (TIS) compared to non-Ethiopia IUs across all baseline categories. We used those estimates to predict when remaining active trachoma-endemic IUs (TF.sub.1-9 [greater than or equal to]5%) would have their last round of mass drug administration (MDA) based on the mean number of years required and number of MDA rounds already completed. Our model predicts that elimination of TF.sub.1-9 will be achieved in 2028 in Ethiopia (95% CI: 2026-2033) and 2029 outside of Ethiopia (95% CI: 2023-2034), with some IUs in East Africa predicted to be the last requiring MDA globally. Our empirical estimate is similar to those resulting from previous susceptible-infectious-susceptible (SIS) and mathematical models, suggesting that the forecast achievement of TF.sub.1-9 elimination is realistic with the caveat that although disease elimination progress can be predicted for most IUs, there is an important minority of IUs that is not declining or has not yet started trachoma elimination activities. These IUs represent an important barrier to the timely global elimination of active trachoma.
BackgroundGreat progress has been made toward the elimination of trachoma as a public-health problem. Mathematical and statistical models have been used to forecast when the program will attain the goal of the elimination of active trachoma, defined as prevalence of trachomatous inflammation-follicular in 1-9 year olds (TF1-9) <5%. Here we use program data to create an empirical model predicting the year of attaining global elimination of TF1-9.Methodology/principal findingsWe calculated the mean number of years (95% CI) observed for an implementation unit (IU) to move from a baseline TF1-9 prevalence ≥5% to the elimination threshold, based on the region (Ethiopia vs. non-Ethiopia) and baseline prevalence category. Ethiopia IUs had significantly different rates of reaching the TF1-9 elimination threshold after a trachoma impact survey (TIS) compared to non-Ethiopia IUs across all baseline categories. We used those estimates to predict when remaining active trachoma-endemic IUs (TF1-9 ≥5%) would have their last round of mass drug administration (MDA) based on the mean number of years required and number of MDA rounds already completed. Our model predicts that elimination of TF1-9 will be achieved in 2028 in Ethiopia (95% CI: 2026-2033) and 2029 outside of Ethiopia (95% CI: 2023-2034), with some IUs in East Africa predicted to be the last requiring MDA globally.Conclusions/significanceOur empirical estimate is similar to those resulting from previous susceptible-infectious-susceptible (SIS) and mathematical models, suggesting that the forecast achievement of TF1-9 elimination is realistic with the caveat that although disease elimination progress can be predicted for most IUs, there is an important minority of IUs that is not declining or has not yet started trachoma elimination activities. These IUs represent an important barrier to the timely global elimination of active trachoma.
Background Great progress has been made toward the elimination of trachoma as a public-health problem. Mathematical and statistical models have been used to forecast when the program will attain the goal of the elimination of active trachoma, defined as prevalence of trachomatous inflammation—follicular in 1–9 year olds (TF1–9) <5%. Here we use program data to create an empirical model predicting the year of attaining global elimination of TF1–9. Methodology/Principal findings We calculated the mean number of years (95% CI) observed for an implementation unit (IU) to move from a baseline TF1–9 prevalence ≥5% to the elimination threshold, based on the region (Ethiopia vs. non-Ethiopia) and baseline prevalence category. Ethiopia IUs had significantly different rates of reaching the TF1–9 elimination threshold after a trachoma impact survey (TIS) compared to non-Ethiopia IUs across all baseline categories. We used those estimates to predict when remaining active trachoma-endemic IUs (TF1–9 ≥5%) would have their last round of mass drug administration (MDA) based on the mean number of years required and number of MDA rounds already completed. Our model predicts that elimination of TF1–9 will be achieved in 2028 in Ethiopia (95% CI: 2026–2033) and 2029 outside of Ethiopia (95% CI: 2023–2034), with some IUs in East Africa predicted to be the last requiring MDA globally. Conclusions/Significance Our empirical estimate is similar to those resulting from previous susceptible-infectious-susceptible (SIS) and mathematical models, suggesting that the forecast achievement of TF1–9 elimination is realistic with the caveat that although disease elimination progress can be predicted for most IUs, there is an important minority of IUs that is not declining or has not yet started trachoma elimination activities. These IUs represent an important barrier to the timely global elimination of active trachoma.
Audience Academic
Author Hooper, P. J
Ngondi, Jeremiah M
Emerson, Paul M
Renneker, Kristen K
AuthorAffiliation 2 RTI International, Washington DC, United States of America
1 International Trachoma Initiative, The Task Force for Global Health, Decatur, Georgia, United States of America
The University of Hong Kong, CHINA
AuthorAffiliation_xml – name: 2 RTI International, Washington DC, United States of America
– name: The University of Hong Kong, CHINA
– name: 1 International Trachoma Initiative, The Task Force for Global Health, Decatur, Georgia, United States of America
Author_xml – sequence: 1
  fullname: Renneker, Kristen K
– sequence: 2
  fullname: Emerson, Paul M
– sequence: 3
  fullname: Hooper, P. J
– sequence: 4
  fullname: Ngondi, Jeremiah M
BookMark eNptktuKFDEQhhtZcQ_6BoINgngzYw7dOXixMC6uLix4s_ehJl09kyGdjEnPgm9v2mllR5ZAKiRf_lRV_svqLMSAVfWWkiXlkn7axUMK4Jf7MHZLQihpBX9RXVDN2wWTvD17sj6vLnPeEdLqVtFX1TkvQTRKXFRfbmNCC3l0YVOPW6zRu8EFGF0MdexrsKN7xHpMYLdxgM_1KtQ47F1yFnw9xA796-plDz7jmzleVQ-3Xx9uvi_uf3y7u1ndL2zL6biwAhB7uUZohF73ZbJK675dM9LoTmrLbEcF51xzEMRy0aBSFqEHZZtS21X17ii79zGbufpsmCScSqJIU4i7I9FF2Jl9cgOkXyaCM382YtoYSKOzHg2DTlnGesaobBgqWLMOWIeMyK6xQhWt6_m1w3rAzmIoLfAnoqcnwW3NJj4azQmTekrm4yyQ4s8D5tEMLlv0HgLGQ8lbKEVUSwUt6Pv_0Oerm6kNlAJc6OP0KZOoWUnKRMMaLQu1fIYqo8PB2eKg3pX9kwsfnlzYIvhxm6M_TAbIp2BzBG2KOSfs_zWDEjM58m_WZnKkmR3JfwMjgtRm
CitedBy_id crossref_primary_10_1093_inthealth_ihae036
Cites_doi 10.3109/09286586.2015.1081249
10.1093/infdis/jir257
10.1787/9789264303201-3-en
10.1016/S0140-6736(11)61515-8
10.1001/jama.299.7.778
10.1371/journal.pntd.0004000
10.1016/S2214-109X(22)00050-X
10.1016/j.epidem.2017.01.007
10.1016/j.ophtha.2019.11.001
10.1093/trstmh/traa170
10.3109/09286586.2015.1037401
10.1093/cid/ciy004
ContentType Journal Article
Copyright COPYRIGHT 2022 Public Library of Science
2022 Renneker et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2022 Renneker et al 2022 Renneker et al
Copyright_xml – notice: COPYRIGHT 2022 Public Library of Science
– notice: 2022 Renneker et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2022 Renneker et al 2022 Renneker et al
DBID AAYXX
CITATION
3V.
7QL
7SS
7T2
7T7
7U9
7X7
7XB
88E
8C1
8FD
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
C1K
CCPQU
DWQXO
F1W
FR3
FYUFA
GHDGH
H94
H95
H97
K9.
L.G
M0S
M1P
M7N
P64
PIMPY
PQEST
PQQKQ
PQUKI
7X8
5PM
DOA
DOI 10.1371/journal.pntd.0010563
DatabaseName CrossRef
ProQuest Central (Corporate)
Bacteriology Abstracts (Microbiology B)
Entomology Abstracts (Full archive)
Health and Safety Science Abstracts (Full archive)
Industrial and Applied Microbiology Abstracts (Microbiology A)
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Public Health Database
Technology Research Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
ProQuest Central
Environmental Sciences and Pollution Management
ProQuest One Community College
ProQuest Central Korea
ASFA: Aquatic Sciences and Fisheries Abstracts
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources
Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality
ProQuest Health & Medical Complete (Alumni)
Aquatic Science & Fisheries Abstracts (ASFA) Professional
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biotechnology and BioEngineering Abstracts
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
Aquatic Science & Fisheries Abstracts (ASFA) Professional
Technology Research Database
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality
Environmental Sciences and Pollution Management
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
AIDS and Cancer Research Abstracts
Health & Safety Science Abstracts
Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Medical Library (Alumni)
ProQuest Public Health
Virology and AIDS Abstracts
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Entomology Abstracts
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ASFA: Aquatic Sciences and Fisheries Abstracts
Engineering Research Database
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
Publicly Available Content Database




MEDLINE - Academic

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Public Health
DocumentTitleAlternate Forecasting the elimination of active trachoma
EISSN 1935-2735
Editor Lau, Eric HY
Editor_xml – sequence: 1
  givenname: Eric HY
  surname: Lau
  fullname: Lau, Eric HY
EndPage e0010563
ExternalDocumentID 2703170804
oai_doaj_org_article_2ad8c22f221742e8ab2da2de207d4c68
A712642497
10_1371_journal_pntd_0010563
GeographicLocations Ethiopia
GeographicLocations_xml – name: Ethiopia
GrantInformation_xml – fundername: ;
  grantid: 7200AA18CA00040
GroupedDBID ---
123
29O
2WC
3V.
53G
5VS
7X7
88E
8C1
8FI
8FJ
AAFWJ
AAYXX
ABDBF
ABUWG
ACGFO
ACIHN
ACPRK
ADBBV
AEAQA
AENEX
AFKRA
AFRAH
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
BENPR
BPHCQ
BVXVI
BWKFM
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EAP
EAS
EBD
ECGQY
EMOBN
ESX
F5P
FPL
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
IHW
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
P2P
PGMZT
PIMPY
PQQKQ
PROAC
PSQYO
PV9
RNS
RPM
RZL
SV3
TR2
TUS
UKHRP
AFPKN
7QL
7SS
7T2
7T7
7U9
7XB
8FD
8FK
AZQEC
C1K
DWQXO
F1W
FR3
H94
H95
H97
K9.
L.G
M7N
P64
PQEST
PQUKI
7X8
5PM
ACUHS
-
AAPBV
ABPTK
BBAFP
PRINS
ID FETCH-LOGICAL-c531t-c6aeef7bea469bf469c899f5b2049d79c2cd1633393a60c364e88ceafa8c4563
IEDL.DBID RPM
ISSN 1935-2735
1935-2727
IngestDate Sun Sep 04 00:10:34 EDT 2022
Tue Dec 17 15:23:27 EST 2024
Tue Sep 17 21:21:07 EDT 2024
Fri Oct 25 04:56:47 EDT 2024
Fri Nov 08 20:46:19 EST 2024
Tue Nov 19 20:53:29 EST 2024
Tue Nov 12 22:56:25 EST 2024
Tue Aug 20 22:11:41 EDT 2024
Fri Nov 22 02:26:39 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Language English
License This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Creative Commons Attribution License
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c531t-c6aeef7bea469bf469c899f5b2049d79c2cd1633393a60c364e88ceafa8c4563
Notes new_version
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
I have read the journal’s policy and the authors of this manuscript have the following competing interests: KKR, PME, and PJH are employees of International Trachoma Initiative, a program of The Task Force for Global Health, which receives an operating budget and research funds from Pfizer Inc., the manufacturers of Zithromax (azithromycin).
ORCID 0000-0003-4357-4816
0000-0002-6478-8816
0000-0001-8036-4776
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302794/
PMID 35816486
PQID 2703170804
PQPubID 1436337
ParticipantIDs plos_journals_2703170804
doaj_primary_oai_doaj_org_article_2ad8c22f221742e8ab2da2de207d4c68
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9302794
proquest_miscellaneous_2688085161
proquest_journals_2703170804
gale_infotracmisc_A712642497
gale_infotracacademiconefile_A712642497
gale_healthsolutions_A712642497
crossref_primary_10_1371_journal_pntd_0010563
PublicationCentury 2000
PublicationDate 20220711
PublicationDateYYYYMMDD 2022-07-11
PublicationDate_xml – month: 7
  year: 2022
  text: 20220711
  day: 11
PublicationDecade 2020
PublicationPlace San Francisco
PublicationPlace_xml – name: San Francisco
– name: San Francisco, CA USA
PublicationTitle PLoS neglected tropical diseases
PublicationYear 2022
Publisher Public Library of Science
Public Library of Science (PLoS)
Publisher_xml – sequence: 0
  name: Public Library of Science (PLoS)
– name: Public Library of Science
References (pntd.0010563.ref019) 2017
AW Solomon (pntd.0010563.ref014) 2015; 22
A Amza (pntd.0010563.ref021) 2017; 64
Word Health Organization (pntd.0010563.ref002) 2021; 96
EM Harding-Esch (pntd.0010563.ref015) 2018
pntd.0010563.ref001
TM Lietman (pntd.0010563.ref023) 2020; 127
pntd.0010563.ref026
pntd.0010563.ref006
SK West (pntd.0010563.ref005) 2011; 204
H. Wickham (pntd.0010563.ref020) 2016
World Health Organization (pntd.0010563.ref003) 2020
World Health Organization (pntd.0010563.ref007) 2015
A Pinsent (pntd.0010563.ref013) 2017; 18
S Blumberg (pntd.0010563.ref027) 2021; 115
pntd.0010563.ref008
KK Renneker (pntd.0010563.ref004) 2022; 10
pntd.0010563.ref009
Expanded Special Project for Elimination of Neglected Tropical Diseases (pntd.0010563.ref028) 2020
F Liu (pntd.0010563.ref012) 2015; 9
International Trachoma Initiative (pntd.0010563.ref017) 2020
T Gebre (pntd.0010563.ref022) 2012; 379
M Melese (pntd.0010563.ref024) 2008; 299
TM Lietman (pntd.0010563.ref010) 2018; 66
pntd.0010563.ref016
M Gambhir (pntd.0010563.ref011) 2015; 22
W Godwin (pntd.0010563.ref025) 2020
pntd.0010563.ref018
NA Fernandez-Santos (pntd.0010563.ref029) 2021; 12
pntd.0010563.ref030
References_xml – volume: 22
  start-page: 394
  issue: 6
  year: 2015
  ident: pntd.0010563.ref011
  article-title: Estimating the Future Impact of a Multi-Pronged Intervention Strategy on Ocular Disease Sequelae Caused by Trachoma: A Modeling Study
  publication-title: Ophthalmic Epidemiol
  doi: 10.3109/09286586.2015.1081249
  contributor:
    fullname: M Gambhir
– ident: pntd.0010563.ref030
– volume: 204
  start-page: 268
  issue: 2
  year: 2011
  ident: pntd.0010563.ref005
  article-title: Number of years of annual mass treatment with azithromycin needed to control trachoma in hyper-endemic communities in Tanzania
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jir257
  contributor:
    fullname: SK West
– ident: pntd.0010563.ref001
– ident: pntd.0010563.ref018
  doi: 10.1787/9789264303201-3-en
– year: 2017
  ident: pntd.0010563.ref019
  publication-title: London School of Hygiene and Tropical Medicine. Trachoma in the Pacific: Research progress
– year: 2016
  ident: pntd.0010563.ref020
  publication-title: Elegant Graphics for Data Analysis
  contributor:
    fullname: H. Wickham
– volume: 379
  start-page: 143
  issue: 9811
  year: 2012
  ident: pntd.0010563.ref022
  article-title: Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster-randomised trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(11)61515-8
  contributor:
    fullname: T Gebre
– volume: 299
  start-page: 778
  issue: 7
  year: 2008
  ident: pntd.0010563.ref024
  article-title: Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma
  publication-title: Jama
  doi: 10.1001/jama.299.7.778
  contributor:
    fullname: M Melese
– ident: pntd.0010563.ref009
– volume: 9
  start-page: e0004000
  issue: 8
  year: 2015
  ident: pntd.0010563.ref012
  article-title: Short-term Forecasting of the Prevalence of Trachoma: Expert Opinion, Statistical Regression, versus Transmission Models
  publication-title: PLoS Negl Trop Dis
  doi: 10.1371/journal.pntd.0004000
  contributor:
    fullname: F Liu
– volume: 10
  start-page: e491
  issue: 4
  year: 2022
  ident: pntd.0010563.ref004
  article-title: Global progress toward the elimination of active trachoma: an analysis of 38 countries
  publication-title: The Lancet Global Health
  doi: 10.1016/S2214-109X(22)00050-X
  contributor:
    fullname: KK Renneker
– year: 2020
  ident: pntd.0010563.ref025
  article-title: Trachoma Prevalence After Discontinuation of Mass Azithromycin Distribution
  publication-title: J Infect Dis
  contributor:
    fullname: W Godwin
– ident: pntd.0010563.ref026
– volume: 96
  start-page: 353
  issue: 31
  year: 2021
  ident: pntd.0010563.ref002
  publication-title: Weekly Epidemiological Record
  contributor:
    fullname: Word Health Organization
– ident: pntd.0010563.ref016
– start-page: 2014
  volume-title: Task Force for Global Health
  year: 2015
  ident: pntd.0010563.ref007
  contributor:
    fullname: World Health Organization
– volume: 64
  start-page: 743
  issue: 6
  year: 2017
  ident: pntd.0010563.ref021
  article-title: A Cluster-Randomized Trial to Assess the Efficacy of Targeting Trachoma Treatment to Children
  publication-title: Clinical Infectious Diseases
  contributor:
    fullname: A Amza
– volume: 18
  start-page: 48
  year: 2017
  ident: pntd.0010563.ref013
  article-title: Probabilistic forecasts of trachoma transmission at the district level: A statistical model comparison
  publication-title: Epidemics
  doi: 10.1016/j.epidem.2017.01.007
  contributor:
    fullname: A Pinsent
– year: 2020
  ident: pntd.0010563.ref017
  publication-title: Global Atlas of Trachoma Decatur, Georgia
  contributor:
    fullname: International Trachoma Initiative
– volume: 127
  start-page: 11
  issue: 1
  year: 2020
  ident: pntd.0010563.ref023
  article-title: Trachoma: Time to Talk Eradication
  publication-title: Ophthalmology
  doi: 10.1016/j.ophtha.2019.11.001
  contributor:
    fullname: TM Lietman
– volume: 12
  start-page: 235
  year: 2021
  ident: pntd.0010563.ref029
  article-title: Historical Review and Cost-Effectiveness Assessment of the Programs to Eliminate Onchocerciasis and Trachoma in Mexico.
  publication-title: Res Rep Trop Med
  contributor:
    fullname: NA Fernandez-Santos
– ident: pntd.0010563.ref008
– volume: 115
  start-page: 222
  issue: 3
  year: 2021
  ident: pntd.0010563.ref027
  article-title: Implications of the COVID-19 pandemic in eliminating trachoma as a public health problem
  publication-title: Trans R Soc Trop Med Hyg
  doi: 10.1093/trstmh/traa170
  contributor:
    fullname: S Blumberg
– ident: pntd.0010563.ref006
– volume: 22
  start-page: 214
  issue: 3
  year: 2015
  ident: pntd.0010563.ref014
  article-title: The Global Trachoma Mapping Project: Methodology of a 34-Country Population-Based Study
  publication-title: Ophthalmic Epidemiology
  doi: 10.3109/09286586.2015.1037401
  contributor:
    fullname: AW Solomon
– year: 2018
  ident: pntd.0010563.ref015
  article-title: Tropical Data: Prevalence Surveys for Elimination of Trachoma and other Negelcted Tropical Diseases
  publication-title: Proceedings of the 14th International Symposium on Human Chlamydial Infections
  contributor:
    fullname: EM Harding-Esch
– volume-title: Elimination of Trachoma in Myanmar
  year: 2020
  ident: pntd.0010563.ref003
  contributor:
    fullname: World Health Organization
– volume: 66
  start-page: S275
  issue: suppl_4
  year: 2018
  ident: pntd.0010563.ref010
  article-title: Models of Trachoma Transmission and Their Policy Implications: From Control to Elimination
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciy004
  contributor:
    fullname: TM Lietman
– volume-title: Recommendations for Safely Restarting MDA for NTDs in Settings with Heightened Risk of COVID-19 Community Transmission
  year: 2020
  ident: pntd.0010563.ref028
  contributor:
    fullname: Expanded Special Project for Elimination of Neglected Tropical Diseases
SSID ssj0059581
Score 2.4089477
Snippet Background Great progress has been made toward the elimination of trachoma as a public-health problem. Mathematical and statistical models have been used to...
Great progress has been made toward the elimination of trachoma as a public-health problem. Mathematical and statistical models have been used to forecast when...
BACKGROUNDGreat progress has been made toward the elimination of trachoma as a public-health problem. Mathematical and statistical models have been used to...
Mathematical and statistical models have been used to forecast the global decline of active trachoma prevalence as a result of interventions against the...
BackgroundGreat progress has been made toward the elimination of trachoma as a public-health problem. Mathematical and statistical models have been used to...
Background Great progress has been made toward the elimination of trachoma as a public-health problem. Mathematical and statistical models have been used to...
SourceID plos
doaj
pubmedcentral
proquest
gale
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
StartPage e0010563
SubjectTerms Biology and Life Sciences
Control
Earth Sciences
Mathematical analysis
Mathematical models
Medicine and Health Sciences
People and Places
Physical Sciences
Public health
Research and Analysis Methods
Statistical analysis
Statistical models
Surveying
Trachoma
Tropical diseases
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Na9wwEBVlD6WX0qYtcZumChR6cmJLsmT3tikNIZCeUshN6GNEA6l3yW7-f2dk7xJBoZdefFjNCvuNR36DNG8Y-5w6AD90rnYppFqJJtau71TdQNKA9DVJTfXO1z_05U91ddvdPmn1RWfCJnngCbgz4WIfhEiCuLOA3nkRnYggGhNV0FOZbyN2ydS0BndDl9uTIjuhiith5qI5adqz2Uen63EbT3ODSC2Lj1LW7t-v0Iv1_WpT0M_y8OSTr9HFK_ZyppF8Od3-a_YMxgP2_HreKH_DzqnlZnAbOtTMkeNxuM_tu8gNfJW4y8scx6mpWYr7ypcjh9_ruywYwnN7nLfs5uL7zbfLem6XUAcMpG0dtANIxoPDlNcnvARMplLnBWYB0QxBhIjsS8pBOt0EqRX0fQCXXB-QRsl3bDGuRjhkvNUR05CIodxK1UXtg1EJp1POt330omL1Di67nkQxbN4ZM5hMTABYgtfO8FbsnDDd25Kkdf4BHW1nR9t_Obpin8gjdqoP3QemXZoWSR1mkaZiX7IFhSbh5-YKA3woErkqLI8KSwypUAwfktd3z7KxglT-DZJrhf_cvQl_Hz7ZD9OkdIJthNUj2mhcKZHe6rZipniDCljKkfHuV1b8Hmh3eVDv_weOH9gLQSUcJA7aHrHF9uERPiKx2vrjHEN_AGkaINk
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fa9UwFA56ByLImFNZt6kRBJ-63SZpkvoi98rGEDZEJuytpPkxB7Otu3f__85J06sF2UsfmtOWnOScfifJOR8hH0PpfVOVJjfBhlywucuNLkU-90F6gK-BS8x3Pr-QZz_Ft6vyKi24rdKxytEnRkftOotr5McMC60rwDfiS_8nR9Yo3F1NFBpPyRYruNYzsrU8ufj-Y_TFZVVGmlJAKZh5xVRKnuOqOE5jddS3a3cUiSIln_ycYg3_jaee9bfdagJDp4co__krne6Q7QQn6WIY_5fkiW93ybPztGG-S14My3J0yDZ6RZZIxWnNCg87U8B-1N9GWi8cHtoFaqL7o_ApJFExn-mipf53fxMLidBIm_OaXJ6eXH49yxONQm7BwNa5lcb7oBpvIBRuAlwsBFmhbBhEB05VllkHqIzzihs5t1wKr7X1JhhtAV7xN2TWdq3fI7SQDsITByZecFE62VglArxOmKbQrmEZyUf11f1QLKOOO2YKgoxBITWqu07qzsgSdbyRxVLX8UZ3d10ny6mZcdoyFhgGT8xr0zBnmPNsrpywUmfkPY5QPeSNbgy2XqgCwB5Elyojn6IEmizqz6TMA-gUFr-aSB5OJMHU7KR5D2fB2JdV_XdSwpPjzPh_84dNM74UT7a1vrsHGQkeFGCvLDKiJjNqopZpS3vzK1YCr3DXuRL7j3_8gDxnmLSB5UCLQzJb3937twCl1s27ZC8PkxoeUA
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3da9RAEB_qCSKIaFWaWnUFwaccl81mNxFErmIpwvnUQt_CfmrhTM67K9j_3pnNBwbalzxkZ_Mxmdn9TXZnfgAfQuG9qQqd6mBDKvjCpbosRLrwQXqEryGXlO-8-iHPL8X3q-LqAAbO1l6BuztDO-KTutyu53__3H5Bh_8cWRtUNnSab5q9m0fKR5k_gIcc50ba5LUS47pCURVl1ifQ3ddzMkHFOv7jaD3brNvdBIpON1L-NzOdPYOnPaRky84GnsOBbw7h0apfND-EJ92vOdZlHL2AU6LjtHpHG54Z4j_m15Haiz4RawPTcQhkeCsiUtGf2LJh_vfmOhYTYZE65yVcnH27-Hqe9lQKqUUn26dWau-DMl5jOGwCHiwGWqEwHCMEpyrLrUNkludVruXC5lL4srReB11ahFj5K5g1beOPgGXSYYji0M2zXBROGqtEwMsJbbLSGZ5AOqiv3nQFM-q4aqYw0OgUUpO6617dCZySjkdZKncdT7Tbn3XvPTXXrrScB04BFPelNtxp7jxfKCesLBN4R1-o7nJHR6etlypDwIcRpkrgY5QgQyL96T77AF-KCmBNJE8mkuhudtJ8RFYwvMuu5sQAoBB4C-w5WMbdze_HZroo7W5rfHuDMhJHUYS-MktATSxqopZpS3P9K1YDr2jluRLH9z_Xa3jMKWmDyoFmJzDbb2_8G4RSe_M2esc_NPIfGg
  priority: 102
  providerName: Scholars Portal
Title Forecasting the elimination of active trachoma: An empirical model
URI https://www.proquest.com/docview/2703170804
https://search.proquest.com/docview/2688085161
https://pubmed.ncbi.nlm.nih.gov/PMC9302794
https://doaj.org/article/2ad8c22f221742e8ab2da2de207d4c68
http://dx.doi.org/10.1371/journal.pntd.0010563
Volume 16
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdtBmMvY5_UW5dpMNiTk1iWJXlvSWgpg5QyOsib0ecWSGzTpP__7hQ71LCnvejBOgvrTif9zroPQr6GwntTFjrVwYaUs5lLtSp4OvNBeICvIRcY77y6FTe_-I91sT4jRR8LE532rdlM6u1uUm_-RN_KdmenvZ_Y9G61LPGyreTTc3IOx29voh-336IsYmVSACYYbMVkFy-Xy2zaiWfS1gc3ibUhBdbRwRRggmM09ZOjKWbwP-3To3bb7AcgdOhC-eRMun5FXnZgks6PH_2anPn6DXm-6q7L35IFFt60eo-uzRSQHvXbWMQLhUGbQHXc7CgMjSVT9Hc6r6nftZuYNoTGIjnvyP311f3yJu2KJqQW1OmQWqG9D9J4DYavCdBYMKlCYRjYAk6WllkHGCzPy1yLmc0F90pZr4NWFsBU_p6M6qb2F4RmwoEx4kChs5wXThgreYDhuDaZcoYlJO3ZVbXH1BhVvB-TYFIcGVAhp6uO0wlZIE9PtJjYOj5oHn5XnXgrpp2yjAWGphLzShvmNHOezaTjVqiEfEaJVMco0ZN6VnOZAbQDW1Im5FukQAVF_ukuzgAmhamuBpSXA0pQLDvovkCp93PZVwxz_UuA2Bze7FfCv7u_nLpxUPRjq33zCDQC9ksAuSJLiBysoAFbhj2gBjHvd7fsP_z3mx_JC4bRG5gXNLsko8PDo_8EmOpgxqBJawmtWmZj8mxxdXv3cxz_T0C74mocdewvGP4mKQ
link.rule.ids 230,314,727,780,784,864,885,2102,2221,12056,12223,21388,24318,27924,27925,31719,31720,33266,33267,33744,33745,43310,43579,43805,53791,53793,73745,74014,74302
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fb9MwELagkwAJIRhMCwxmJCSesjWOYye8oBZtKrBWCBVpb5bjHzBpJGHt_n_uHKcQCfGSh_iSyGff5Tvbdx8hb3zhXF0VOtXe-JSzqU11WfB06rxwAF99LjDfebkSi2_802VxGRfcNvFY5eATg6O2rcE18lOGhdYl4Bv-vvuVImsU7q5GCo27ZA8rpxcTsjc_W335OvjioioCTSmgFMy8YjImz-UyO41jddI1W3sSiCJFPvo5hRr-O0896a7bzQiGjg9R_vVXOn9MHkU4SWf9-D8hd1yzT-4t44b5PnnYL8vRPtvoKZkjFafRGzzsTAH7UXcdaL1weGjrqQ7uj8KnkERFv6Ozhrqf3VUoJEIDbc4zsj4_W39YpJFGITVgYNvUCO2cl7XTEArXHi4Ggixf1AyiAysrw4wFVJbnVa7F1OSCu7I0TntdGoBX-QGZNG3jDgnNhIXwxIKJZzkvrKiN5B5ex3WdlbZmCUkH9amuL5ahwo6ZhCCjV4hCdauo7oTMUcc7WSx1HW60N99VtBzFtC0NY55h8MRcqWtmNbOOTaXlRpQJOcYRUn3e6M5g1UxmAPYgupQJeRsk0GRRfzpmHkCnsPjVSPJoJAmmZkbNhzgLhr5s1J9JCU8OM-Pfza93zfhSPNnWuPYWZAR4UIC9IkuIHM2okVrGLc3Vj1AJvMJd54o____Hj8n9xXp5oS4-rj6_IA8YJnBgadDsiEy2N7fuJcCqbf0q2s5vF9QhOA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9RAEF_0CkUQ0ao0tdoVBJ_Su2w2u4kvcqc96kePIhX6tmz2Qws1SXvX_9-ZzeY0IL7kITtJyOzM7G9254OQN75wrq4KnWpvfMrZzKa6LHg6c144gK8-F5jvfLYSp9_558viMsY_rWNY5WATg6G2rcE98inDQusS8A2f-hgWcf5x-b67SbGDFJ60xnYa98kOrIozNiE7i5PV-bfBLhdVEVqWAmLBLCwmYyJdLrNpnLfjrtnY49A0UuSjhSrU899a7Ul33a5HkHQcUPnXCrV8TB5FaEnnvSw8Ifdcs0d2z-Lh-R552G_R0T7z6ClZYFtOo9cY-EwBB1J3HVp84VTR1lMdTCGFT2FDFf2OzhvqfnVXoagIDS10npGL5cnFh9M0tlRIDSjbJjVCO-dl7TS4xbWHiwGHyxc1A0_BysowYwGh5XmVazEzueCuLI3TXpcGoFb-nEyatnH7hGbCgqtiQd2znBdW1EZyD6_jus5KW7OEpAP7VNcXzlDh9EyCw9EzRCG7VWR3QhbI4y0tlr0ON9rbHypqkWLaloYxz9CRYq7UNbOaWcdm0nIjyoQc4QypPod0q7xqLjMAfuBpyoS8DRSovsg_HbMQ4KewENaI8nBECWpnRsP7KAXDv6zVHwGFJwfJ-Pfw6-0wvhSj3BrX3gGNAGsKEFhkCZEjiRqxZTzSXP0MVcErPIGu-MH_P35EdkFt1NdPqy8vyAOGuRxYJTQ7JJPN7Z17CQhrU7-KqvMbqYglZQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Forecasting+the+elimination+of+active+trachoma%3A+An+empirical+model&rft.jtitle=PLoS+neglected+tropical+diseases&rft.au=Kristen+K.+Renneker+https%3A%2F%2Forcid.org%2F0000-0001-8036-4776&rft.au=Paul+M.+Emerson+https%3A%2F%2Forcid.org%2F0000-0002-6478-8816&rft.au=Hooper%2C+P&rft.au=Jeremiah+M.+Ngondi+https%3A%2F%2Forcid.org%2F0000-0003-4357-4816&rft.date=2022-07-11&rft.pub=Public+Library+of+Science&rft.eissn=1935-2735&rft.volume=16&rft.issue=7&rft_id=info:doi/10.1371%2Fjournal.pntd.0010563&rft.externalDocID=2703170804
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1935-2735&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1935-2735&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1935-2735&client=summon